Prognostic significance of thrombocytosis in patients with primary lung cancer

European Respiratory Journal

Volumn 9, Issue 9, 1996, Pages 1826-1830

  Moller Pedersen L ^a,b   Milman, N ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

Author keywords

Lung canceer; Platelet count; Prognostic factors; Thrombocytosis; Tumour markers

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT; THROMBOCYTOSIS;

EID: 0029815666     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09091826     Document Type: Article

References (42)

1. Riess L. Zur pathologischen Anatomie des Blutes. Arch Anat Physiol Wissensch Med 1872; 39: 237-249.
2. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med 1964; 114: 497-500.
3. Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987; 88: 596-602.
4. Dutcher JA. Hematologic abnormalities in patients with nonhematologic malignancies. Hematol Oncol Clin N Am 1987; 1: 281-299.
5. Nand S, Gross-Fisher S, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 1987; 5: 1998-2003.
6. Ascensao JL, Oken MM, Ewing SL, Goldberg RJ, Kaplan ME. Leukocytosis and large cell lung cancer. Cancer 1987; 60: 903-905.
7. Souhami RL, Bradbury J, Geddes DM, Spiro SG, Harper PG, Tobias JS. Prognostic significance of laboratory parameters measured at prognosis in small cell carcinoma of the lung. Cancer Res 1985; 45: 2878-2882.
8. Østerlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46: 4189-4194.
9. Cohen MH, Makuch R, Johnston-Early A, et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small lung cancer. Cancer Treat Rev 1981; 65: 187-195.
10. Warrell RP Jr, Bockman RS, Staszewski H, Maiese K. Clinical study of a new antimetastatic compound, nafazatrom (Bay g 6575): effects on platelet consumption and monocyte prostaglandin production in patients with advanced cancer. Cancer 1986; 57: 1455-1460.
11. Gislason T, Nou E. Sedimentation rate, leucocytes, platelet count and haemoglobin in bronchial carcinoma: an epidemiological study. Eur J Respir Dis 1985; 66: 141-146.
12. Engan T, Hannisdal E. Blood analyses as prognostic factors in primary lung cancer. Acta Oncologica 1990; 29: 151-154.
13. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 225-233.
14. Histological typing of lung tumours. 2nd edn. Geneva, World Health Organization, 1981.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Peto R, Pike MC, Armitage R, et al. Design and analysis of clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-47.
17. Cox DR. Regression model and life tables. J R Stat Soc (Series B) 1972; 34: 187-220.
18. BMDP statistical software. Berkeley, CA, University of California Press, 1981.
19. Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992; 69: 2975-2977.
20. Zeimet AG, Marth C, Müller-Holzner E, Daxenbichler G, Dapunt O. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1994; 170: 549-554.
21. Chalas E, Welshinger M, Engellener W, Chumas J, Barbieri R, Mann WJ. The clinical significance of thrombocytosis in women presenting with a pelvic mass. Am J Obstet Gynecol 1992; 166: 974-977.
22. Constantini V, Zacharski LR, Moritz TE, Edwards RL. The platelet count in carcinoma of the lung and colon. Thromb Haemost 1990; 64: 501-505.
23. Silvis SE, Turkbas N, Doscherholmen A. Thrombocytosis in patients with lung cancer. JAMA 1979; 211: 1852-1853.
24. Diehl WL, Mandelbaum I. The significance of thrombocytosis in patients with carcinoma of the lung. Surg Gynecol Obstet 1983; 156: 187-188.
25. Nakano T, Fujii J, Tamura S, Hada T, Higashino K. Thrombocytosis in patients with malignant pleural mesothelioma. Cancer 1986; 58: 1699-1701.
26. Wajima T, Mukhopadhyay P. Serial coagulation profiles in patients with small cell carcinoma of the lung (Abstract). Thromb Haemost 1989; Suppl. 62: 136.
27. Spigel SC, Mooney LR. Extreme thrombocytosis associated with malignancy. Cancer 1977; 39: 339-341.
28. Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM. Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 1994; 74: 90-92.
29. Rodriguez GC, Clarke-Pearson DL, Soper JT, Berchuck A, Synan I, Dodge RK. The negative prognostic implications of thrombocytosis in women with stage Ib cervical cancer. Obstet Gynecol 1994; 83: 445-448.
30. Honn KV, Tang DC, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 1992; 11: 325-351.
31. Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ. Thrombospondin: a potentiator of tumor cell metastasis. Cancer Res 1978; 47: 4130-4133.
32. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred and eight patients. Part 1. Coagulation studies. Am J Clin Pathol 1979; 71: 10-16.
33. Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237-248.
34. Buss DH, Cashell AW, O'Connor ML, Richards F, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994; 96: 247-253.
35. Lieberman JS, Borrero J, Urdaneta E, Wright IS. Thromboembolism associated with neoplasm: review of seventy seven cases. JAMA 1961; 177: 542-545.
36. Miller SP, Sanchez-Avalos J, Stefanski T, Zuckerman L. Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer 1967; 20: 1452-1456.
37. Alexander MB. Iron deficiency anemia, thrombocytosis, and cerebrovascular accident. South Med J 1983; 76: 662-663.
38. Knizley H, Noyes WD. Iron deficiency anemia, papilledema, thrombocytosis and transient hemiparesis. Arch Intern Med 1972; 129: 483-486.
39. Imai T, Koike K, Kubo T, et al. Interleukin-6 supports human megakaryocyte proliferation and differentiation in vitro. Blood 1991; 78: 1969-1964.
40. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC Jr, Brown EL. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 1989; 83: 921-926.
41. Gastl G, Plante M, Finstad CL, et al. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993; 83: 433-441.
42. Hollen CW, Henthorn J, Koziol JA, Burstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol 1991; 79: 286-290.